Prasad: Pharma companies lack capabilities and struggle to attract top AI talent
G. V. Prasad · Two Pharma Giants Who'd Never Met | Mankind & Dr. Reddy's | WTF is Pharma? · Nikhil Kamath · Jun 17, 2026 · at 2:37:33
G.V. Prasad, Co-Chairman and MD of Dr. Reddy's Laboratories, discusses startup opportunities providing specialized AI services to the pharmaceutical sector.
0:00 / 0:39exact quote · 39.1s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“So the AI part is a big deal for us and we are not equipped to do it. Whether it's in our Salesforce management, targeting doctors, all of that can be driven much more efficiently. Through agents and things like that. Our processes, R&D processes can improve. Now we are able to do, ah, in silico experiments, in silico organoids. These are all areas where they can be services to pharma, which we don't have the capabilities to. And we can't attract the talent. A smart AI guy doesn't want to work for a you know, pharmaceutical company.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from G. V. Prasad
Prasad: Dr. Reddy's clinical trials found no significant medical efficacy in turmeric
“We've done trials with turmeric, we didn't see significant.”
Prasad: Dr. Reddy's found Chinese suppliers more reliable than Indian peers during COVID
“In COVID time, I'm telling you this, in COVID time, we had more reliable supplies from China than from Indian companies.”
Prasad: E-pharmacies are highly capital intensive and Tata 1mg remains unprofitable
“Online business can happen, but then you require a huge amount of capital. It's not a twenty-five-year-old's job. Tata MG, One MG is still not profitable.”
Prasad: Scaling hospital chains is difficult because it is fundamentally real estate
“I think it's a very difficult game to scale because it's a real estate play at the end of the day.”
Prasad: US 100% tariffs on non-US innovative drugs threaten Indian CDMOs
“No, if you're selling it to the US, and it's an innovative drug, not a generic drug, and it's not manufactured in the US, it's manufactured in India, there is a likelihood of a hundred percent tariff. So this affects our CDMO industry, the contract development…”